Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J M Gore

Showing results (141-150 of 165) with videos related to

Pageof 17
Sort By:
Circulation|June 3, 1997
Incidence and predictors of bleeding after contemporary thrombolytic therapy for myocardial infarction. The Global Utilization of Streptokinase and Tissue Plasminogen activator for Occluded coronary arteries (GUSTO) I InvestigatorsS D Berkowitz, C B Granger, K S Pieper, et al.
Journal of the American College of Cardiology|May 1, 1996
A composite view of cardiac rupture in the United States National Registry of Myocardial InfarctionR C Becker, J M Gore, C Lambrew, et al.
Circulation|October 1, 1994
Treatment of myocardial infarction in the United States (1990 to 1993). Observations from the National Registry of Myocardial InfarctionW J Rogers, L J Bowlby, N C Chandra, et al.
Heart (British Cardiac Society)|June 19, 2007
Outcomes with the use of glycoprotein IIb/IIIa inhibitors in non-ST-segment elevation acute coronary syndromesO H Dabbous, F A Anderson, J M Gore, et al.
Circulation|August 1, 1986
Preliminary experience with synchronized coronary sinus retroperfusion in humansJ M Gore, B H Weiner, J R Benotti, et al.
Circulation|January 1, 1985
Effect of bepridil in patients with chronic stable angina: results of a multicenter trialJ A Hill, J T O'Brien, J S Alpert, et al.
Annals of Internal Medicine|August 15, 1991
Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II TrialE G Bovill, M L Terrin, D C Stump, et al.
Journal of the American College of Cardiology|April 1, 1991
Selective versus routine predischarge coronary arteriography after therapy with recombinant tissue-type plasminogen activator, heparin and aspirin for acute myocardial infarction. TIMI II InvestigatorsW J Rogers, J D Babb, D S Baim, et al.
Heart (British Cardiac Society)|August 19, 2003
Creatinine clearance and adverse hospital outcomes in patients with acute coronary syndromes: findings from the global registry of acute coronary events (GRACE)J J Santopinto, K A A Fox, R J Goldberg, et al.
The New England Journal of Medicine|August 31, 1995
Regional variation across the United States in the management of acute myocardial infarction. GUSTO-1 Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary ArteriesL Pilote, R M Califf, S Sapp, et al.
Pageof 17

Showing results (141-150 of 165) with videos related to

Sort By:
Pageof 17
Circulation|June 3, 1997
Incidence and predictors of bleeding after contemporary thrombolytic therapy for myocardial infarction. The Global Utilization of Streptokinase and Tissue Plasminogen activator for Occluded coronary arteries (GUSTO) I InvestigatorsS D Berkowitz, C B Granger, K S Pieper, et al.
Journal of the American College of Cardiology|May 1, 1996
A composite view of cardiac rupture in the United States National Registry of Myocardial InfarctionR C Becker, J M Gore, C Lambrew, et al.
Circulation|October 1, 1994
Treatment of myocardial infarction in the United States (1990 to 1993). Observations from the National Registry of Myocardial InfarctionW J Rogers, L J Bowlby, N C Chandra, et al.
Heart (British Cardiac Society)|June 19, 2007
Outcomes with the use of glycoprotein IIb/IIIa inhibitors in non-ST-segment elevation acute coronary syndromesO H Dabbous, F A Anderson, J M Gore, et al.
Circulation|August 1, 1986
Preliminary experience with synchronized coronary sinus retroperfusion in humansJ M Gore, B H Weiner, J R Benotti, et al.
Circulation|January 1, 1985
Effect of bepridil in patients with chronic stable angina: results of a multicenter trialJ A Hill, J T O'Brien, J S Alpert, et al.
Annals of Internal Medicine|August 15, 1991
Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II TrialE G Bovill, M L Terrin, D C Stump, et al.
Journal of the American College of Cardiology|April 1, 1991
Selective versus routine predischarge coronary arteriography after therapy with recombinant tissue-type plasminogen activator, heparin and aspirin for acute myocardial infarction. TIMI II InvestigatorsW J Rogers, J D Babb, D S Baim, et al.
Heart (British Cardiac Society)|August 19, 2003
Creatinine clearance and adverse hospital outcomes in patients with acute coronary syndromes: findings from the global registry of acute coronary events (GRACE)J J Santopinto, K A A Fox, R J Goldberg, et al.
The New England Journal of Medicine|August 31, 1995
Regional variation across the United States in the management of acute myocardial infarction. GUSTO-1 Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary ArteriesL Pilote, R M Califf, S Sapp, et al.
Pageof 17